Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.
Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects, according to investigators.
NRG 0815 is a “landmark” study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer.
Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.
Men diagnosed with prostate cancer during 2020, the start of the pandemic, were more likely to have higher-stage and higher-grade disease compared with men diagnosed in 2018-2019, according to investigators.
